Compare Enveric Biosciences Inc (ENVB) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Icl Group Ltd — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Icl Group Ltd trades at $5.3 (market cap $6.94B). The key difference: Icl Group Ltd is far larger — about 1119.4× Enveric Biosciences Inc's market cap, and Icl Group Ltd pays a 3.86% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | ICL | |
|---|---|---|
Market Cap | $6.20M | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $17.40 | $6.84 |
52-Week Low | $1.27 | $4.80 |
Enterprise Value | $1.30M | $9.57B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
ICL trades at $5.31, up 0.76% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The company reported $7.15B revenue in 2025, with net income of $226M, and maintains a P/E of 22.13 and P/S of 0.89. Recent news highlights Q2 sales growth driven by potash and bromine prices, alongside a cost-transformation program.
Outlook is mixed: earnings momentum and dividend payments offer support, but declining profit margins and 100% hold analyst consensus indicate caution. Key risks include raw material cost volatility and geopolitical factors affecting the specialty minerals market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
